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Objective sleep in CFS 
Abstract 
Background:  Sleep disturbance affects almost 95% of people with chronic fatigue syndrome (CFS). 
However, existing studies of sleep in CFS have shown mixed results and methodological issues 
prevent between-study comparisons.  
Purpose:  To redress this, the present study aimed to investigate whether there are differences in 
the sleep of patients with CFS and healthy controls, using a comparative analysis of 
Polysomnography over three consecutive nights.  
Methods:  22 patients with CFS (1994 Centers for Disease Control and Prevention criteria) and 22 
healthy controls underwent three nights of polysomnographic sleep assessment. Groups were 
compared on their objective sleep variables derived from the third night of assessment, to allow for 
participant adaptation to the sleep study. 
Results:  9.1% of patients met criteria for an objectively verifiable sleep disorder. Differences in sleep 
were observed between CFS patients and healthy controls on four objectively-derived sleep 
variables (wake after sleep onset, sleep efficiency, percentage wake and REM Latency). In addition, 
people with CFS reported more severe symptoms of insomnia than healthy controls. 
Conclusions:  The study reports on key differences in sleep between people with CFS and healthy 
individuals. The potential presence of a sleep disorder in this patient population is high, it is 
therefore important that during early evaluation, a detailed history of sleep is taken to rule out a 
sleep disorder in CFS. In addition, patients with CFS show poorer sleep as defined by objectively-
derived measures and also self-report poorer quality sleep.  Improving sleep is a potential treatment 
target in CFS.   
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Objective sleep in CFS 
Introduction 
Chronic Fatigue Syndrome (CFS) affects between 0.2% - 4% of the UK population1, making it a 
significant healthcare issue. Characterized by intense persistent or relapsing fatigue of at least 6 
months in duration, CFS affects both physical and cognitive functioning and is associated with other 
symptoms such as myalgia, concentration difficulties and sleep disturbance2.  CFS has the largest 
prevalence of an objective sleep disorder in any single illness population3-6, with rates as high as 
65%7, and 87-95% of patients continue to report unrefreshing sleep as a principle complaint after 
excluding individuals with diagnosable sleep disorders 8-11.  
 
Polysomnography (PSG) is considered the gold standard objective sleep assessment. Despite the 
prevalence of sleep problems in CFS, studies using PSG in CFS populations have not been uniform in 
their data reporting or methodological practices12-13. As such, there remains no clear pattern of sleep 
abnormality in this population. One characteristic of PSG research in CFS that may account for this is 
the high degree of variability in sleep continuity and sleep architecture features that are reported in 
CFS studies, making it difficult to interpret results and determine the nature and extent of patients’ 
sleep difficulties. Furthermore, PSG studies in CFS have mostly been carried out over one night6, 7, 14-
21, or two22-30, which may present a potential ‘first night effect’ (i.e, when a person has a different 
sleeping pattern to usual, as a result of a sleep study)24. The assumptions regarding the variability 
and lack of consistency in objective sleep patterns of patients with CFS rests on the idea that patients 
experience the first-night-effect. A seminal study explored this phenomenon in 83 CFS patients 
without an objectively verifiable sleep disorder and observed clear differences between the first and 
second night sleep parameters25, all indicating a poorer first night sleep, in comparison to night two. 
Both the first night effect and the potential for rebound sleep (better sleep resulting from a 
previous poor night) highlight the need for at least a 3-night assessment for PSG research with CFS 
patients. 
 
Objective sleep in CFS 
CFS diagnosis is based on a collection of symptoms, which creates difficulties in making definitive 
conclusions, however, given the probable reciprocal effects of disturbed sleep on existing CFS 
symptoms, the sleep of patients with CFS should be looked at in as much detail as possible.  This 
study aimed to redress the inconsistencies in previous studies reporting polysomnographic-derived 
results from CFS populations and compare the sleep of individuals with CFS and healthy controls on 
the third recorded night of sleep.  
 
Methods  
Recruitment of participants 
22 CFS patients were recruited from a specialist CFS Service in the North of England, and fulfilled the 
CDC 1994 diagnostic criteria2.  22 healthy controls were recruited from a bank of participants held by 
the Northumbria Centre for Sleep Research (NCSR). All included subjects were aged between 18 and 
65 and free from any sleeping medication for at least 3 weeks prior to recording (Table 2).  Six CFS 
patients (40%) were taking sleep-altering medications at participation (selective serotonin re-uptake 
inhibitors, N = 6; gabapentin, N = 1). Five were taking one sleep-altering medication and one 
participant was on both a selective serotonin re-uptake inhibitor (SSRI) and Gabapentin.  
 
Exclusion criteria for all subjects were: a) those currently seeing a sleep medicine specialist, b) a 
diagnosis of Obstructive Sleep Apnoea (OSA), Periodic Limb Movement Disorder (PLMD) or 
Narcolepsy, c) those who had travelled beyond one time zone within three months of study 
participation, and d) shift-workers. Regular sleep-wake schedules and circadian normality were 
assessed through Actigraphy and adjunct sleep diaries two weeks prior to the start of the study. 
Actigraphy was used to complement the sleep diary, and was not used in any further analyses.  Sleep 
Disorders (OSA, PLMD) were ruled out following night one of the PSG assessment, if individuals met 
AASM exclusionary criteria (i.e, if the Apnoea Hypopnoea Index (AHI; number of Apnea or Hypopnea 
events per hour of sleep) was greater than 5, and/or a Periodic Limb Movement Index (PLMI; rate of 
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leg movements per hour of sleep) greater than 5). 
 
Ethical approval was granted by the Newcastle and North Tyneside local research ethics 
committee, and all participants provided written informed consent. 
 
Procedure 
Prior to the 3-day assessment, participants were required to complete a sleep diary over a 14-day 
pre-assessment period. During this time, participants were also required to complete the Pittsburgh 
Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI). To assess daytime symptoms in the 
CFS group, the Chalder Fatigue Questionnaire and Short Form-36 Health Survey (SF-36) were 
completed by patients. All participants underwent three consecutive nights of polysomnography 
assessment, to reduce the potential for a ‘first-night’ effect and a rebound night. To allow for greater 
participation, the CFS cohort underwent ambulatory PSG assessment in their homes.  
 
Objective Sleep Assessment 
Polysomnography. Polysomnography (PSG) was carried out over 3 consecutive nights. The first two 
study nights served as screening and an opportunity for participant adaptation. Recordings were 
conducted in accordance with International 10/20 standards on all 3 nights31, and an extended 
montage was used on night 1 (Figure 1).  Oral and nasal airflow were measured by a nasal cannula, 
capillary oxygen saturation by finger-oxymetry and respiratory effort by thoracic and abdominal 
belts (See eMethods1 in the supplement for details of the PSG recording).  
 
 
[Insert Figure 1 here] 
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Outcome Measures 
The Pittsburgh Sleep Quality Index (PSQI) 33 evaluated sleep quality over the previous month. 
19 self-rated items are combined to form 7 component scores (subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, 
daytime dysfunction), responses are rated on 4-point Likert scale (0=no difficulty, 3=severe 
difficulty). Component scores are summed to yield a global score that has a possible range of 0-21 
(0=no difficulty, 21=severe difficulties in all areas). A global PSQI score greater than 5 suggests poor 
quality sleep.   
The Insomnia Severity Index (ISI) is a reliable and valid tool for detecting cases of insomnia in 
a population34. 7 items evaluate the severity of sleep onset, sleep maintenance, early morning 
awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime 
functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. 
Responses are rated on a 5-point Likert scale (0 = no problem; 4 = very severe problem) yielding a 
total score (0 -28). Scores can determine an absence of insomnia (0-7), subthreshold insomnia (8-14) 
or ‘caseness’ for clinical insomnia (15-21), with 10 or more considered optimal for detecting 
insomnia cases34.Convergent validity is supported by high ISI scores being significantly correlated 
with QoL and fatigue33.  The Ford Insomnia Response to Stress Test (FORD) is a 9-item screening tool 
to identify individuals predisposed to developing insomnia, testing the likelihood that an individual 
will have sleep disturbances following stressful events. 
Objective Sleep Variables included Sleep onset latency (SOL), Total sleep period (TSP), Total 
sleep time (TST), Number of awakenings (NWAK), Sleep efficiency index (SEI), REM (Non Rapid Eye 
Movement) sleep, REM (Rapid Eye Movement) latency (REML) (See Table 1) (See eMethods 1 in the 
supplement for detailed sleep variable parameters). 
 
(Insert Table 1 Here) 
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Daytime symptoms 
The Chalder Fatigue Questionnaire (CFQ) 35 was used to measure symptomatic fatigue experienced 
by patients in this study. Four response options are available, ranging from ‘‘less than usual’’ to 
‘‘much more than usual’. The Likert system for scoring was used (0-3) with a total possible score 
ranging from 0-33. A higher score indicates more fatigue.  The test has been shown by its authors to 
have good reliability (r =.86 for physical fatigue, and r =.85 for mental fatigue) and has high internal 
consistency as measured by Cronbach’s alpha (.89) 35. The Short Form Health Survey (SF-36)36 was 
used to assess health status, functioning, and well-being as a measure of Quality of Life (QoL) across 
eight domains, both physically and emotionally based. Lower values reflect more impairment. 
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS version 22. An independent samples t-test was 
used to examine which demographic variables and polysomnography-derived sleep variables 
differentiated the groups. Multiple Regression analyses examined the extent to which sleep 
predicted patient’s daytime symptoms (see eResults 1). All values are expressed as mean ± SD unless 
otherwise stated.   
 
Results 
Following the first night of recording, 2 (9.1%) CFS patients were excluded from the study, having met 
the exclusionary criteria for sleep apnea (A+H Indexes: 15.5 and 7.1). Data for one CFS patient was 
excluded due to no nocturnal sleep having been recorded, due to daytime sleep, following the third 
study night. There were no further exclusions. The final dataset included 19 CFS patients, and 22 
healthy control participants. All patients completed the three overnights of home-based 
polysomnographic assessment including morning sleep diary completion. This 0% rate of attrition 
indicates that this 3-day sleep assessment protocol was both feasible and acceptable to patients who 
were eligible to take part in this study. 
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There were no between-group differences on sex (p=0.12) or BMI (p=0.46). There were no significant 
differences in sleep parameters between the second and third nights of assessment (data not 
shown) and therefore the third night data is presented. In relation to the polysomnography 
variables, differences in objective sleep were observed between CFS patients and healthy controls 
on four objectively-derived sleep variables (wake after sleep onset (p<0.05), sleep efficiency 
(p<0.05), percentage of wake (p<0.01) and REM Latency (p<0.05) (see Table 2), and six self-reported 
facets of sleep quality (PSQI), including insomnia severity (ISI) (see Table 3). There were no group 
differences in sleep onset latency (SOL) (p =0.06), TST (p =0.57), percentage of stage 1 (p =0.28) 
sleep, percentage of stage 2 sleep (p =0.71), percentage of stage 3 (SWS) (p =0.26) sleep, or 
percentage of REM (p= 0.60). There were also no differences between CFS patients and healthy 
controls on number of awakenings (NWAK) (p=0.08).   
  
(Insert Table 2 Here) 
 
 
 Self-reported sleep 
There were significant group differences on all but one component of the PSQI. Global scores were 
poorer for CFS patients than healthy controls (p<.001). In addition, CFS patients had poorer scores on 
‘sleep Latency’ (p<.001), ‘Subjective Sleep Quality’ (p<.001), ‘Sleep Duration’ (p<.05), ‘Sleep Efficiency’ 
(p<.05), and ‘Sleep Disturbances’ (p<.001), and ‘Daytime Dysfunction’ (p<.01). There were no significant 
differences observed on the ‘Medication Use’ (p=0.07) component (Table 3).  100% of patients had 
PSQI global scores of 5 or more, exceeding the threshold that is indicative of poor quality sleep (≥5). 
Scores ranged from 5 to 17 points (mean=8.75, SD=3.45). For individual components (subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of 
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sleeping medication, daytime dysfunction), each with a possible range of 0-3, the observed ranges 
were 0-3 (Table 3). 
 
There were significant differences in self-reported insomnia severity between CFS patients and 
healthy controls (p<.001). Observation of self-reported sleep difficulties showed CFS patients had 
mean ISI scores (13.74, SD=4.81) which indicated  ‘sub-threshold insomnia’, with  52.6%  (10/19)  
of  patients  reporting  sleep difficulties meeting  criteria  for  this  range  (8-14).  42.1% of patients  
(8/19) met ‘caseness’ for clinically defined insomnia (ISI score 15-21)), and one patient’s sleep 
difficulties were classified as ‘severe’ (>21) 34.  
 
 (Insert Table 3 Here) 
 
Subjective vs Polysomnographic assessment of sleep 
Interestingly, based on the retrospective measures of sleep (PSQI, ISI, FIRST), patients scored highly 
across all assessments for reporting sleep difficulties and poor quality sleep.  On the other hand, the 
objectively-derived PSG measures shed a different light; patients’ sleep profiles on the whole 
appeared to reflect 'normal sleep' parameters, presenting abnormalities on the continuity variable 
WASO, and in the architectural variables of %WAKE and REM latency. 
 
It is therefore of interest to explore this discrepancy further. To evaluate the level of concordance 
between the two assessment modalities; self-reported measures of sleep based on the sleep diary; 
and the objectively derived Polysomnographic variables (PSG), a Pearson product-moment 
correlation was carried out to determine the level of agreement between corresponding sleep 
variables (TST, SOL, WASO) derived from the two assessment modalities. 
 
(Insert Table 4 Here) 
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TST as measured by the PSG (453.91 ± 73.74 minutes) and TST self-reported on the sleep diary 
(448.68 ± 101.31 minutes) were significantly correlated, r = .65, p < .01, indicating a strong positive 
relationship between objectively derived (PSG) measures of total sleep time and total sleep time as 
self-reported (sleep diary) by patients (See Table 4). Patients were therefore accurately estimating 
their sleep duration. However, there was a nonsignificant correlation of .21 (p = n.s) between SOL 
measured by the PSG (mean= 22.47, SD= 20.49 minutes) and SOL self-reported on the sleep diary 
(mean=33.95, SD=21.67 minutes).   There was also a nonsignificant correlation of .32 (p = n.s) 
between WASO measured by the PSG (mean= 37.13, SD=24.32 minutes) and WASO self- reported on 
the sleep diary (mean= 41.58, SD=56.48 minutes) (Table 4). This indicates that patients were 
overestimating the amount of time it took them to get to sleep and the amount of time they were 
spending awake during the night. 
 
Discussion 
The study aimed to investigate objective differences in the sleep of patients with CFS and 
healthy controls, using Polysomnography over three consecutive nights. Sleep on the third 
night allowed for adaptation and potential rebound sleep was compared. Patients with CFS 
differed from the healthy healthy control group on four objectively-derived sleep variables with 
significant differences observed on WASO, SE, REML and %Wake; the CFS patient group had the 
highest amount of wake after sleep onset and percentage of wake, and longer REM latencies 
than the healthy control group. Although differences in sleep efficiency were observed, these 
were in the normal range (>85%) for both groups. CFS patients also reported significantly 
poorer sleep quality and more severe insomnia-related symptoms than the healthy control 
group.  
 
A key clinical observation in the study was the longer REM latency in the CFS group. REM sleep 
Objective sleep in CFS 
is the period by which learning and memory consolidation are believed to occur, it therefore 
seems plausible to consider this stage of sleep and how it may be involved in CFS, as this 
condition features key symptoms such as brain fog, memory and concentration difficulties. 
REM sleep represents the most highly aroused brain state during sleep and appears the most 
vulnerable to fragmentation in individuals who demonstrate persistent hyperarousal - a 
potential contributor to the experience of disrupted and nonrestorative sleep - a result of 
enhanced arousal and more conscious perception of the environment during sleep37. REM sleep 
should be a focus for future sleep research in CFS, given its association with poor quality sleep38 
and a potential perpetuating factor for other symptoms. Such disruptions in the normal sleep 
process suggest that a potential ‘REM Sleep Instability’ (RSI)  may be an objective marker for 
CFS39. 
 
Prior to the sleep assessment, patients self-reported their sleep as disturbed and of poor quality, as   
demonstrated by   the   retrospective   self-report measures.   However, on   initial examination of 
patients’ sleep profiles, based on objectively derived measures (PSG), on average they fell into the 
parameters of ‘normal’ sleep.  The variability in values derived on each of the sleep parameters is of 
relevance; it highlights how a significant minority of the sample fell outside of the ‘normal’ 
parameters, a reflection of the heterogeneity of sleep, and is also characteristic of patient’s sleep 
profiles as identified in the previous studies. For example, increased amounts of stage 2 sleep 
mirrors what has been shown in patients characterised by the second phenotype identified in the 
cluster analysis of CFS patients from our recent study5, and its association with information 
processing, arousability and the  perception  of  sleep  in  fibromyalgia patients  has  also  been  
demonstrated41. Alpha activity (a shallow form of sleep), has been associated with an increased 
tendency to arouse to external stimuli in fibromyalgia patients, and to the perception of more 
shallow sleep, but interestingly not related to pain41. This increased arousability could be trans-
diagnostic for functional symptoms; the tendency for patients to arouse more during sleep may 
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result in more fragmented sleep, as suggested by Shneider-Helmert and colleagues43, which in turn 
has been implicated in daytime fatigue and nonrestorative sleep44, fundamental symptom 
complaints of patients with CFS. 
 
Combining methods of sleep assessment enabled the examination of sleep variables derived from 
the different assessment modalities (subjective sleep diary vs objective PSG).  Patients were accurate 
in their estimation of sleep duration.  However, estimations of wake duration and the time it took 
them to get to sleep were not concordant with the objectively derived measures. This finding mirrors 
the discrepancy found between subjective and objective measures of sleep, previously seen in CFS; 
Watson and colleagues45 demonstrated no differences between the healthy and CFS twins on 
objective measures of sleep abnormalities despite significant self- reported sleep complaints from 
the CFS twins. This suggests CFS patients require an objective assessment of their sleep pattern, and 
these objective methods have been shown to be feasible in this population.  
 
The protocol was possible in all eligible patients that took part, which emphasises the feasibility of 
incorporating all the included procedures of a detailed 3-night PSG sleep assessment. Overall, the 
protocol was well tolerated, with only minor issues relating to individuals and their experience of the 
equipment (sensitivity, planning, energy depletion). Also it is worth emphasising how several 
patients brought to light of the issue of daytime sleep, and this also posed a problem with regard to 
analyses, where a night of PSG data for one patient had to be excluded due to no nocturnal sleep 
having been recorded, and the possible presence of a sleep disorder in this patient. Daytime sleep 
is recognisable in this population46, and it has been associated with having a negative impact on 
daytime symptoms47, this warrants further study. 
 
In addition to establishing protocol feasibility in this patient group, we established a profile of sleep 
in patients, derived from sleep in a naturalistic setting across 3 consecutive nights. The temporal 
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stability of sleep continuity and main architectural variables across two consecutive nights of 
assessment was also confirmed. This PSG protocol therefore affords, if needed, the efficacy to carry 
out two rather than three nights of recording. Of note, variability of sleep was confirmed to  exist  in  
this  population,  and,  as  such,  the  establishment  of  a successful protocol for effective and 
thorough sleep assessment is a key advancement in this domain .  
 
There are some limitations to the design of this study. The CFS group underwent sleep assessment in 
the home setting. This enabled greater participation and generalizability to a patient group whose 
symptoms are often disabling, and allowed participation of the more severely affected, a sub-group 
often overlooked in research. Ideally a healthy control group should have also been studied in the 
home setting, given that people may sleep differently in the lab to how they would usually in their 
own home. Despite the potential for differences in sleep between the unattended home and the 
attended laboratory PSG setting, previous home vs lab investigations have observed only modest 
effects on sleep parameters, an overall difference similar to that expected based on night-to-night 
variation in sleep40,41. Of note, participants in the study significantly differed on age. And, by not 
including those with sleep apnea, sleep phase disorders or narcolepsy, it is plausible that a crucial 
subgroup of patients are being missed, with sleep disorders that may be contributing to fatigue, or 
comorbid to CFS. Future work may want to age-match the control participants to the CFS patient 
group, and also look at comparing CFS patients with and without a comorbid sleep disorder, or the 
presence of OSA. Although participants were free from sleep medication prior to taking part, those 
taking anti-depressants were not excluded. Anti-depressant medication increases REM latency, 
which makes it difficult to determine whether the longer REM latencies observed in patients are due 
to the sleep altering medication or a feature of CFS. 
 
Despite patients’ demonstrating impairments in symptoms of fatigue and social functioning, there 
was no relationship between objective sleep and symptoms in patients (see eResults1 in 
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supplement), suggesting that further work is needed to explore the relationship between sleep 
abnormalities and fatigue in this patient group, and that formal sleep studies are needed. 
 
Moving forward in advancing sleep research in CFS populations, this study afforded the opportunity 
to establish an objective profile of sleep in a group of CFS patients, based on assessment of sleep in 
a naturalistic setting, over 3 consecutive nights.  By carrying out home sleep studies with people with 
CFS, the findings are more generalizable to patients, who may otherwise not be able to participate in 
such research studies. It is important to note the exclusion of one patient’s data due to an 
absence of nocturnal sleep recorded, and also, with PSG there is always the potential for day-
to-day variability in objective sleep variables, which should be considered 48. Future objective 
sleep studies in CFS may wish to explore sleep fragmentation, where there have been advances in 
methods to quantify this aspect of sleep. Studies should also consider daytime PSG assessment, 
thus extending the monitoring of patient’s sleep to ensure their entire sleep period is characterized, 
given sleeping during the day, is highly likely in a CFS patient group.  It would also be of value 
for future studies to incorporate daytime multiple sleep latency tests (MSLT) to measure 
excessive sleepiness during the day, in trying to determine a problem with sleep, and identify 
and rule out possible narcolepsy as an underlying sleep disorder, where it can often 
mistakenly be labelled as CFS. Future, more complete studies should also look in more detail 
at the demographics of sleep disorders in this group of patients, which can present more 
than one syndrome. 
 
In summary, the objective data show that the sleep of people with CFS is different from those 
without the condition, particularly in relation to sleep efficiency, wake and REM latency. Those with 
CFS also self-report poorer sleep quality and more severe insomnia ratings than healthy controls. In 
CFS, detailed sleep evaluation and systematic PSG screening early on will help to identify and exclude 
diagnosable sleep disorders, which are important contributors to fatigue. 
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Objective sleep in CFS 
Table 1: Description of sleep variables 
 
 
 
Notes: REM, rapid eye movement; TSP, total sleep period; TST, total sleep time; arousal defined as an abrupt shift in EEG 
frequency (alpha, theta waves and/or frequencies greater than 16 Hz, but not sleep spindles), lasting at least 3s, after at least 
10 continuous seconds of sleep, and is associated with sleep fragmentation (Iber et al., 2007).  
 
 
 
 
 
 
Abbreviated 
Variable 
Sleep Variable (measure) Description 
AHI Apnea /Hypopnea Index Number of Apnea or Hypopnea events during sleep 
TST Total Sleep Time 
(minutes) 
 
Amount of time asleep 
SOL Sleep Onset Latency 
(minutes) 
Length of time from lights out to first episode of stage 2 
sleep 
 
WASO Wake After Sleep Onset 
(minutes) 
Number of minutes of recorded wake following first 
episode of stage 2 sleep 
 
NWAK Number of Awakenings 
(over TSP) 
Number of wake bouts following first episode of stage 2 
sleep 
 
NoA Number of Arousals Number of arousals over the entire sleep period 
 
REML REM Latency 
 
Length of time to first REM stage 
 
 
SE (%) Sleep Efficiency Percentage of time spent asleep from the amount of time 
spent in bed (TST/TIB*100) 
 
%N1 Percentage of Stage 1 (of 
TST) 
Percentage of recorded stage 1 sleep over the total time 
asleep 
 
%N2 Percentage of  Stage 2 (of 
TST) 
Percentage of recorded stage 2 sleep over the total time 
asleep 
 
%SWS Percentage of SWS (of 
TST) 
Percentage of recorded slow wave sleep over the total 
time asleep 
 
%REM Percentage of REM (of 
TST) 
Percentage of recorded Rapid Eye Movement sleep over 
the total time asleep 
 
%WAKE Percentage of  WAKE (of 
TSP) 
Percentage of recorded wake over the whole sleep period 
(from lights out to lights on) 
Objective sleep in CFS 
Table 2: Characteristics of study participants, and sleep variables derived from nocturnal 
polysomnography for the two groups, from the third recorded night. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: BMI, body mass index; CFS, chronic fatigue syndrome; HC, healthy controls; TSP, total sleep period; TST, total sleep 
time; REM, rapid eye movement. 
Values are given as Mean (SD); values are from the third recorded night (night 1 and night 2 data not shown). 
 
 
 
 
 
 
 
 
 CFS (N=19) HC (N=22) t-
test 
P Value 
Demographics     
     Sex 5 males (26.32%) 11 males (50%) 1.56 ns 
     Age (years) 44.63 (9.74) 25.18 (5.86) 7.87 p<.001 
     BMI 26.09 (3.89) 25.18 (3.57) 0.75 ns 
Sleep Variables     
     Total Sleep Time (min) 442.39 (85.85) 430.43 (30.08) 0.61 ns 
     Sleep Onset Latency (min) 28.95 (29.55) 14.73 (11.41) 2.09 ns 
     Wake After Sleep Onset (min) 42.16 (42.26) 15.86 (12.41) 2.79 p<.05 
     Number of Awakenings (over TSP) 18.37 (10.34) 13.64 (4.88) 1.92 ns 
     REM Latency (min) 140.00 (84.33) 89.45 (30.91) 2.62 p<.05 
     Percentage of N1 (of TST) 4.33 (2.11) 3.70 (1.39) 1.15 ns 
     Percentage of N2 (of TST) 53.15 (11.58) 52.08 (4.47) 0.40 ns 
     Percentage of N3 (SWS) (of TST) 17.07 (10.38) 20.02 (4.43) -1.21 ns 
     Percentage of REM (of TST) 25.45 (8.11) 24.33 (4.92) 0.54 ns 
     Percentage of Wake (of TSP) 13.01 (9.39) 6.54 (3.75) 2.97 p<.01 
     Sleep Efficiency Index (%) 91.64 (7.35) 96.52 (2.37) -2.95 p<.05 
Objective sleep in CFS 
 
 
 
 
 
Table 3:  Retrospective sleep disturbances, self-reported by patients with CFS and healthy controls. 
 
Self-reported sleep disturbance CFS (N=19) HC (N=22)
  
t-test P Value 
             SF-36 (global) 29.50 ± 17.91 na - - 
             SF-36 (physical) 25.00 ± 14.42 na - - 
             SF-36 (energy/fatigue) 19.00 ± 15.78 na - - 
             PSQI (subjective sleep quality) 1.53 ± 0.70 0.64 ± 0.49 4.77 p<.001 
             PSQI (sleep latency) 1.89 ± 0.94 0.82 ± 0.59 4.47 p<.001 
             PSQI (sleep duration) 0.68 ± 0.95 0.18 ± 0.39 2.28 p<.05 
             PSQI (habitual sleep efficiency)          0.84 ± 1.07 0.18 ± 0.50 2.59 p<.05 
             PSQI (sleep disturbances) 1.74 ± 0.45 1.00 ± 0.44 5.30 p<.001 
             PSQI (use of sleep medication) 0.63 ± 1.11 0.09 ± 0.43 2.03 ns 
             PSQI (daytime dysfunction) 1.53 ± 0.96 0.59 ± 0.50 3.97 p<.01 
             PSQI (global)            8.84 ± 3.51 3.45 ± 1.77 6.33 p<.001 
             ISI 13.74 ± 4.81 2.64 ± 2.19 9.74 p<.001 
Notes: CFS, chronic fatigue syndrome; HC, healthy controls; PSQI, Pittsburgh sleep quality index; ISI, insomnia severity 
index. 
Values are given as Mean ± SD 
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Table 4: Comparison of Sleep Parameters: PSG vs. Sleep Diary: Pearson Product- Moment 
Correlation Coefficients. 
 
 
 
 
Sleep Parameters 
 Means
a
  Correlation  
PSG  Diary Pearson r p (2-tailed) 
 
 
TST (min) 
 
 
453.91 
  
 
448.68 
 
 
.65 
 
 
.003
*
 
 (73.74)  (101.31)   
 
SOL (min) 
 
22.47 
  
33.95 
 
.21 
 
.379 
 (20.49)  (21.67)   
 
WASO (min) 
 
37.13 
  
41.58 
 
.32 
 
.179 
 (24.32)  (56.48)   
Notes: N =19 aValues are means; values in parentheses are standard deviations.*p ˂ .01 
TST, total sleep time; SOL, sleep onset latency; WASO, wake after sleep onset; PSG, polysomnography 
Values based on an average of night 2 and night 3. 
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Figure1: The Polysomnogram 
 
 
 
Notes: EEG, electroencephalography; EOG, electrooculography, EMG, electromyography; 
ECG, electrocardiography PSG, polysomnography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
